Store in original package until time of use. Argatroban: Discard product if it contains particulate matter, is cloudy, or discolored – Do not freeze – Protect from . Baxter U.S. – Healthcare Professionals – ARGATROBAN Injection in % Sodium Chloride mg/ mL (1 mg/1 mL). Argatroban is approved by the US Food and Drug Administration .. 51 to minutes), package insert recommendations provide guidance on.
|Published (Last):||18 November 2012|
|PDF File Size:||19.68 Mb|
|ePub File Size:||15.88 Mb|
|Price:||Free* [*Free Regsitration Required]|
For patients receiving sodium-containing intravenous fluids, symptom control and lithium concentrations should be carefully monitored. The constituted solution must be mixed by repeated inversion of the diluent bag or bottle for one minute.
Moderate Due to the risk of bleeding with natural antineoplastics, patients should receive other agents that may increase the risk of bleeding, such as anticoagulants. One vial with 2. For example, concurrent use of oxandrolone and warfarin may result in unexpectedly large increases in the INR or prothrombin time PT. If concurrent therapy is warranted, significant initial dosage reductions e.
[Full text] Update on argatroban for the prophylaxis and treatment of heparin-indu | JBM
Before Exembol Multidose is administered, heparin therapy should be discontinued and a baseline aPTT value obtained. Vial before opening 3 years see Section 6. Clinical experience with argatroban for heparin-induced thrombocytopenia in a large teaching hospital. Biotransformation The metabolism of argatroban has not yet been fully characterized. On termination of the infusion, the concentration of argatroban decreased rapidly. After the initial dose of Exembol Multidose, the dose can be adjusted based on the clinical course until the steady-state aPTT is within the desired therapeutic range 1.
In general, there have been no reported patterns of abnormal coagulation parameters in patients receiving tipranavir, or preceding the development of ICH. Severe and in some cases fatal reactions have been reported following lepirudin sensitization.
Major Platelet aggregation may be impaired by selective serotonin reuptake inhibitors SSRIs due to platelet serotonin depletion, possibly increasing the risk of a bleeding complication in patients receiving thrombin inhibitors. The efficacy and safety of administering injectable collagenase to a patient taking an anticoagulant within 7 days before the injection are unknown.
Date of revision of the text. HIT type I is a benign nonimmune form with a reversible mild thrombocytopenia, which usually resolves despite persistent heparin treatment.
Do not refrigerate or freeze. In clinical trials, there have been 14 reports of intracranial bleeding intracranial hemorrhage, ICHincluding 8 fatalities, in 13 out of 6, HIV infected patients receiving tipranavir as part of combination antiretroviral therapy.
The target value for INR should be within the therapeutic range for co-therapy according to the type of assay used see above for at least 2 days before Exembol Multidose is discontinued.
Exembol Multidose should be used during pregnancy only if treatment is clearly necessary. Argatroban is administered by intravenous infusion. Major and Minor hemorrhagic reactions have been observed in clinical trials. During the 30 day pacoage period thrombotic events occurred during argatroban administration in two patients and following argatroban discontinuation in three argatrobah patients.
Moderate Give the extended-release injectable suspension of naltrexone cautiously to patients taking anticoagulants. Pediatric patients with hepatic impairment: Major During and after therapy, avoid the concomitant use of Yttrium Y ibrutumomab tiuxetan with drugs that argatrobann with coagulation such as anticoagulants; the risk of bleeding may be increased. Careful monitoring of the INR and necessary adjustment of the warfarin dosage are also recommended when the androgen therapy is packate or discontinued.
Monitor patients who are taking anticoagulants closely and adjust anticoagulation therapy as necessary. Carefully monitor sodium concentrations and fluid status if sodium-containing drugs and corticosteroids must be used together. Moderate Androgens can enhance the effects of anticoagulants. The diluted solution should be clear and practically free from visible particles. There is evidence that a reduced initial dose may also be advisable for patients with heart failure, multiple organ packave, severe anasarca, or after cardiac surgery.
Argatroban has been studied in patients with hepatic disease and HIT requiring anticoagulation; however, a lower arvatroban dose should be used. After dilution Diluted solutions should not be exposed to direct sunlight.
Exembol Multidose 100 mg/ml concentrate for solution for infusion
Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction. An increase in the frequency of monitoring is recommended to ensure the target aPTT values are achieved and maintained. Moderate Cautious use of injectable collagenase by patients taking anticoagulants is advised. If coadministration of 2 or more anticoagulants is necessary, patients should be closely monitored for evidence of bleeding.
Symptomatic and supportive therapy should be provided to the patient. Dasatinib can cause serious and fatal bleeding. If possible, intramuscular injections should be avoided in patients receiving argatroban. Special populations Older people: The current review presents the pharmacology of argatroban, data regarding monitoring of the agent, and an overview of the results of the major clinical trials assessing argatroban anticoagulation in HIT patients.
Clinical practice guidelines recommend argatroban or bivalirudin over other nonheparin anticoagulants in patients with heparin-induced thrombocytopenia who require percutaneous coronary intervention. In patients undergoing PCI, these were chest pain, hypotension, back pain, nausea, vomiting, and headache. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme.
Avoid concurrent use of herbs which interact with warfarin when possible.